Fridays Tirzepatide Cost With Insurance 2026: What's Covered, What Isn't & Cash-Pay Alternatives

Editorial Disclosure Luma Health competes with Fridays in the GLP-1 telehealth market. This guide is written from a competitive position. We have aimed to represent how insurance interacts with compounded GLP-1 platforms like Fridays and Luma Health accurately.

Direct Answer: Fridays does not accept insurance for compounded tirzepatide. Like most compounded GLP-1 telehealth platforms, Fridays operates on a cash-pay basis — insurance is not billed and cannot be applied to compounded tirzepatide prescriptions. The "with insurance" cost of Fridays tirzepatide is the same as the "without insurance" cost: whatever Fridays' current cash-pay monthly rate is.

Why Compounded Tirzepatide Is Not Covered by Insurance

Understanding why insurance doesn't cover compounded tirzepatide requires understanding the difference between brand-name and compounded medications. Zepbound is the FDA-approved brand-name tirzepatide manufactured by Eli Lilly. When insurance covers tirzepatide, it covers Zepbound — a specific FDA-approved drug product listed in the insurer's formulary. Insurance does not cover compounded tirzepatide because compounded medications are not FDA-approved as finished drug products. They are prepared per individual prescription by licensed 503A compounding pharmacies, and insurance formularies only list FDA-approved drug products.

This applies uniformly to Fridays, Luma Health, Henry Meds, Hims, Found, and every other platform prescribing compounded tirzepatide. None of them can bill insurance for compounded tirzepatide. All operate on a cash-pay basis for this medication pathway.

What Insurance Covers (and Doesn't) for Tirzepatide

✓ What Insurance May Cover

✓ Brand-name Zepbound (tirzepatide) with prior authorization for obesity
✓ Brand-name Mounjaro (tirzepatide) for type 2 diabetes (more commonly covered)
✓ Provider consultation fees (may count toward deductible)
✓ Lab work associated with clinical treatment
✓ Some employer plans explicitly covering GLP-1 for obesity since 2025

✗ What Insurance Does NOT Cover

✗ Compounded tirzepatide (not an FDA-approved finished drug)
✗ Fridays' cash-pay program fees
✗ Luma Health's subscription fees
✗ Any compounded GLP-1 from any telehealth platform
✗ Zepbound for weight loss on most Medicare and Medicaid plans

Insurance Coverage Reality for Tirzepatide in 2026

Tirzepatide Insurance Coverage by Plan Type — 2026

Large employer commercial insurance — Post-2025 many employers expanded GLP-1 obesity coverage. Per KFF (2024), approximately 19% of large employers covered GLP-1 for obesity. That percentage has grown. Call your insurer and ask specifically: "Does my plan cover Zepbound for weight management?" Possible — verify

ACA marketplace plans — The 2025 Biden administration rule to require GLP-1 coverage for obesity was overturned. Coverage varies by plan; some include Zepbound, most do not. Varies

Medicare Part D — GLP-1 medications for weight loss are generally excluded from Medicare coverage unless used for type 2 diabetes. The Inflation Reduction Act changes did not include GLP-1 obesity coverage for Medicare. Usually No

Medicaid — GLP-1 for obesity coverage varies by state. Some state Medicaid programs cover Wegovy or Zepbound; many do not. Check your state's Medicaid drug formulary. Varies by state

Compounded tirzepatide (any platform) — No insurance covers compounded tirzepatide from any platform, including Fridays, Luma Health, Henry Meds, or any other compounded GLP-1 provider. No — all platforms

ⓘ If You Have Insurance That Covers Tirzepatide If your insurance covers Zepbound for obesity, the right pathway is brand-name Zepbound through your insurer — not a compounded platform like Fridays or Luma Health. With commercial insurance + prior authorization + Eli Lilly's Zepbound savings card (available for commercially insured patients), brand Zepbound cost can reduce to approximately $25/month. Platforms with strong insurance navigation for Zepbound include Calibrate and Ro Body. Compounded platforms like Fridays and Luma Health are cash-pay alternatives for patients without applicable insurance coverage.

Fridays Tirzepatide Cash-Pay Pricing vs Alternatives

Since Fridays (and all compounded tirzepatide platforms) are cash-pay only, the relevant comparison for patients without insurance coverage is the cash-pay monthly rate. Fridays' specific tirzepatide pricing should be verified directly at getfridays.com, as rates can change. The general market range for compounded tirzepatide in 2026:

Provider	Compounded Tirz Price	Dose-Tier Increases	Pharmacy Named	Annual Total (est.)
Henry Meds	~$179/mo (annual)	None (flat)	No	~$2,148
Found	~$199–$249/mo	Yes	No	~$2,388–$2,988
★ Luma Health	$297/mo flat	None (flat)	✓ VialsRX TX#35264	$3,564 flat
Fridays	Verify at getfridays.com	Verify at getfridays.com	Verify	Verify
Hims	~$199–$329/mo (dose-tier)	Yes	No	~$2,388–$3,948
Brand Zepbound (ins.)	~$25/mo (ins. + savings card)	N/A	✓ Eli Lilly	~$300/yr (best case)

Note that brand Zepbound through insurance with prior authorization is dramatically less expensive than any cash-pay compounded option when coverage is available. The entire compounded tirzepatide market — including Fridays and Luma Health — exists primarily for patients who don't have applicable insurance coverage and need a cash-pay pathway to the same active molecule.

What to Do If You Want Insurance to Cover Tirzepatide

The steps to pursue insurance coverage for tirzepatide are distinct from enrolling in a compounded telehealth platform:

Step 1 — Call your insurer directly. Ask specifically: "Does my plan cover Zepbound (tirzepatide) for chronic weight management? What is the prior authorization process?" Provide your plan ID and ask for the specific formulary tier and any step-therapy requirements.

Step 2 — If covered, work with a provider who supports prior authorization. Not all telehealth providers support brand Zepbound prior authorization. Platforms with meaningful insurance navigation infrastructure include Calibrate and Ro Body. Luma Health and Fridays are cash-pay compounded platforms — they do not navigate insurance for brand Zepbound.

Step 3 — If denied or not covered, evaluate cash-pay compounded options. If your insurance doesn't cover Zepbound for obesity (common for Medicare, Medicaid, and plans without GLP-1 obesity coverage), compounded tirzepatide on a cash-pay basis is the cost-effective pathway to the same active molecule. Compare providers by price, pharmacy transparency, and commitment requirements.

Frequently Asked Questions

Does Fridays accept insurance for tirzepatide?

No. Fridays prescribes compounded tirzepatide on a cash-pay basis, as do all compounded GLP-1 telehealth platforms. Insurance does not cover compounded tirzepatide because compounded medications are not FDA-approved finished drug products. Insurance formularies only include FDA-approved brand-name drugs like Zepbound (tirzepatide). Fridays cannot bill your insurance for compounded tirzepatide, and patients pay out-of-pocket at Fridays' published cash-pay rate. Verify Fridays' current pricing directly at getfridays.com.

How much does Fridays tirzepatide cost without insurance?

Fridays' specific tirzepatide pricing should be verified directly at getfridays.com as rates change periodically. As a cash-pay compounded tirzepatide platform, Fridays' pricing is in the general market range of $149 to $329/month for compounded tirzepatide depending on dose tier and plan structure — though specific current rates require direct verification. Compare Fridays' verified pricing against alternatives: Henry Meds (~$179/mo flat, annual), Found (~$199–$249/mo), and Luma Health ($297/mo flat) to determine the best value for your specific situation.

Can I use FSA/HSA funds for Fridays tirzepatide?

Compounded tirzepatide prescribed for a medical condition (obesity with qualifying BMI) by a licensed clinician is generally eligible for FSA and HSA reimbursement as a prescription medication expense. However, FSA/HSA eligibility for compounded medications can depend on your specific plan administrator's interpretation. Verify with your FSA/HSA administrator before assuming eligibility. Many patients who cannot use insurance for GLP-1 do successfully use FSA/HSA accounts for their compounded tirzepatide subscription, which can provide effective cost reduction through pre-tax dollars.

Is there a way to get tirzepatide covered by insurance if I'm using Fridays?

Not through Fridays directly. If you want insurance to cover tirzepatide, you need brand-name Zepbound obtained through a provider and pharmacy that can initiate prior authorization with your insurer. This is a separate pathway from what Fridays and other compounded platforms offer. If you have commercial insurance that may cover Zepbound for obesity, work with a platform that has insurance navigation infrastructure (Calibrate, Ro Body) rather than a compounded-only platform. If insurance approval is obtained, brand Zepbound with a savings card can cost as little as $25/month — far less than any cash-pay compounded option.

Is Luma Health's tirzepatide the same as Fridays'?

Both Fridays and Luma Health prescribe compounded tirzepatide — the same active pharmaceutical molecule (tirzepatide) at equivalent pharmacological doses, prepared by licensed 503A compounding pharmacies. The SURMOUNT-1 trial data (22.5% average weight loss at 72 weeks at the 15 mg dose) applies to the tirzepatide molecule regardless of which platform prescribes it. The differences between platforms are in pricing, pharmacy transparency, dose-tier structures, and bundled services — not in the medication's clinical efficacy at equivalent doses.

Why is compounded tirzepatide cheaper than brand Zepbound?

Brand Zepbound ($1,000–$1,300/month at retail) carries the costs of FDA drug approval, large-scale manufacturing, regulatory compliance, and Eli Lilly's research and development. Compounded tirzepatide ($149–$329/month depending on platform) is prepared per prescription by licensed compounding pharmacies, bypassing these large-scale manufacturing and regulatory costs. The active ingredient is the same molecule at equivalent doses; the cost difference reflects the manufacturing and regulatory structure, not the clinical effect. Compounded tirzepatide is not itself an FDA-approved drug product — it's the clinical mechanism and molecule that are equivalent.

References

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed
Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48. PubMed
FDA. Zepbound (tirzepatide) Prescribing Information. FDA.gov
FDA. Human Drug Compounding — Section 503A. FDA.gov
KFF. Health Benefits Survey: GLP-1 Coverage for Obesity Among Employers. 2024. kff.org
Eli Lilly. Zepbound Savings Program for Commercially Insured Patients. zepbound.lilly.com
Fridays. Official Website. getfridays.com
NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov

Medical Disclaimer: This article is for educational purposes only. Luma Health competes with Fridays — readers should consider our competitive bias. Fridays pricing should be verified at getfridays.com. Insurance coverage for tirzepatide varies significantly by plan — verify with your insurer directly. Clinical services at Luma Health are provided by Wasef Health, PC. Compounded medications prepared by VialsRX, TX Board #35264.